1997
Late sequelae of treatment of Hodgkin's disease
DeVita V. Late sequelae of treatment of Hodgkin's disease. Current Opinion In Oncology 1997, 9: 428-431. PMID: 9327220, DOI: 10.1097/00001622-199709050-00006.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseEarly-stage Hodgkin's diseaseLow-dose radiotherapyStage Hodgkin's diseaseRadiation treatment fieldLate sequelaeSecond malignanciesCombination chemotherapySuccessful treatmentClinical trialsFull dosesBreast cancerLeukemia riskSolid tumorsLow dosesYoung womenDiseaseChemotherapyTreatmentDosesTreatment fieldEarlier reportsRiskYearsReport
1996
Oncology
DeVita V, Deisseroth A. Oncology. JAMA 1996, 275: 1833-1834. PMID: 8642736, DOI: 10.1001/jama.1996.03530470061036.Peer-Reviewed Original Research
1991
Superiority of ProMACE-CytaBOM Over ProMACE-MOPP in the Treatment of Advanced Diffuse Aggressive Lymphoma
Longo D, DeVita V, Duffey P, Wesley M, Ihde D, Hubbard S, Gilliom M, Jaffe E, Cossman J, Fisher R, Young R. Superiority of ProMACE-CytaBOM Over ProMACE-MOPP in the Treatment of Advanced Diffuse Aggressive Lymphoma. Journal Of Clinical Oncology 1991, 9: 710-710. DOI: 10.1200/jco.1991.9.4.710.Peer-Reviewed Original Research
1988
Cytogenetic Studies in Patients With Secondary Leukemia/Dysmyelopoietic Syndrome After Different Treatment Modalities
Whang-Peng J, Young R, Lee E, Longo D, Schechter G, DeVita V. Cytogenetic Studies in Patients With Secondary Leukemia/Dysmyelopoietic Syndrome After Different Treatment Modalities. Blood 1988, 71: 403-414. DOI: 10.1182/blood.v71.2.403.403.Peer-Reviewed Original ResearchCytogenetic studiesChromosomal abnormalitiesStructural abnormalitiesLoss of chromosome 7De novo leukemiaAbstract Cytogenetic studiesCytogenetic abnormalitiesRadiation therapyExtensive chemotherapyNumerical abnormalitiesTreatment modalitiesSerial studiesChemotherapyPatientsAbnormalitiesTreatment groupsHematological changesChromosome 7SyndromeTreatmentChromosome 3HypodiploidyLeukemiaAneuploidyTherapyCytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities.
Whang-Peng J, Young R, Lee E, Longo D, Schechter G, DeVita V. Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood 1988, 71: 403-14. PMID: 3337904, DOI: 10.1182/blood.v71.2.403.bloodjournal712403.Peer-Reviewed Original ResearchConceptsChromosomal abnormalitiesStructural abnormalitiesLoss of chromosome 7Cytogenetic studiesDe novo leukemiaCytogenetic abnormalitiesRadiation therapyExtensive chemotherapyNumerical abnormalitiesTreatment modalitiesSerial studiesChemotherapyPatientsAbnormalitiesTreatment groupsHematological changesChromosome 7SyndromeTreatmentChromosome 3HypodiploidyLeukemiaAneuploidyTherapy
1987
The evolution of chemotherapy of lymphomas of adults.
DeVita V. The evolution of chemotherapy of lymphomas of adults. Leukemia 1987, 1: 467-85. PMID: 3312842.Peer-Reviewed Original ResearchDecreasing Risk of Leukemia with Prolonged Follow-up after Chemotherapy and Radiotherapy for Hodgkin's Disease
Blayney D, Longo D, Young R, Greene M, Hubbard S, Postal M, Duffey P, DeVita V. Decreasing Risk of Leukemia with Prolonged Follow-up after Chemotherapy and Radiotherapy for Hodgkin's Disease. New England Journal Of Medicine 1987, 316: 710-714. PMID: 3821809, DOI: 10.1056/nejm198703193161203.Peer-Reviewed Original ResearchConceptsRisk of leukemiaHodgkin's diseaseAcute leukemiaNormal marrow morphologyBone marrow aspirationAcute nonlymphocytic leukemiaSecond neoplasmsMarrow aspirationNonlymphocytic leukemiaMarrow morphologyActuarial analysisPatientsBone marrowFirst treatmentPeak onsetLeukemiaMorphologic changesChemotherapyRadiation treatmentDiseaseComplicationsTreatmentRiskYearsPrevious studies
1986
Twenty years of MOPP therapy for Hodgkin's disease.
Longo D, Young R, Wesley M, Hubbard S, Duffey P, Jaffe E, DeVita V. Twenty years of MOPP therapy for Hodgkin's disease. Journal Of Clinical Oncology 1986, 4: 1295-306. PMID: 3528400, DOI: 10.1200/jco.1986.4.9.1295.Peer-Reviewed Original ResearchConceptsEnd of treatmentHodgkin's diseaseComplete responseDisease patientsLymphocyte-depleted typeHodgkin's disease patientsHigher CR rateResults of treatmentMOPP therapyB symptomsIntercurrent illnessComplete remissionLonger remissionsCR rateHodgkin's lymphomaLonger survivalBiopsy specimensPatientsHigh dosesDiseaseRemissionLymphomaMore cyclesTreatmentLarge cells
1984
25 THERAPEUTIC RESEARCH IN THE NATIONAL CANCER INSTITUTE
DeVita V, Goidin A. 25 THERAPEUTIC RESEARCH IN THE NATIONAL CANCER INSTITUTE. 1984, 499-526. DOI: 10.1016/b978-0-12-667980-9.50032-4.Peer-Reviewed Original ResearchCombination of drugsTypes of tumorsNational Cancer InstituteGroup of diseasesDosage scheduleCancer therapistClinical oncologistsCancer InstituteExperimental animalsBeneficial effectsTherapeutic researchTumorsDrugsTreatmentSignificant numberField of medicineRemissionChemotherapyPatientsSurgeryOncologistsRadiotherapyCancerDiseasePhysicians
1981
Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease
Schilsky R, Sherins R, Hubbard S, Wesley M, Young R, DeVita V. Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. The American Journal Of Medicine 1981, 71: 552-556. PMID: 7282743, DOI: 10.1016/0002-9343(81)90205-9.Peer-Reviewed Original ResearchConceptsOvarian failureMOPP chemotherapyOvarian functionChemotherapy-induced ovarian failureAge 25Causes of amenorrheaCompletion of chemotherapyPercent of patientsLong-term followTime of evaluationTime of treatmentPersistent amenorrheaChemotherapy regimenOlder patientsMedian ageHodgkin's diseaseEstradiol levelsSerum gonadotropinPatientsAmenorrheaChemotherapyNormal childrenWomenDiseaseTreatmentNatural history of malignant lymphomas with divergent histologies at staging evaluation
Fisher R, Jones R, Devita V, Simon R, Garvin A, Berard C, Young R. Natural history of malignant lymphomas with divergent histologies at staging evaluation. Cancer 1981, 47: 2022-2025. PMID: 7226096, DOI: 10.1002/1097-0142(19810415)47:8<2022::aid-cncr2820470820>3.0.co;2-v.Peer-Reviewed Original ResearchConceptsDifferent histologic diagnosesHistologic diagnosisNatural historyStaging evaluationMalignant lymphomaDiffuse patternNodular patternTissue sitesComplete response rateInitial staging evaluationNational Cancer InstituteMultiple tissue sitesMedian survivalMedical recordsCancer InstituteDivergent histologyPatientsBiopsyResponse ratePlanning treatmentUnique natural historyDiagnosisMonthsLymphomaTreatmentCurrent results of the screening program at the division of cancer treatment, national cancer institute
Goldin A, Venditti J, Macdonald J, Muggia F, Henney J, Devita V. Current results of the screening program at the division of cancer treatment, national cancer institute. European Journal Of Cancer 1981, 17: 129-142. PMID: 6894902, DOI: 10.1016/0014-2964(81)90027-x.Peer-Reviewed Original ResearchConceptsNational Cancer InstituteScreening programCancer treatmentClinical trialsCancer InstituteHuman tumorsProspective screening programInadequate clinical trialsCategories of drugsActivity of drugsRenal capsuleClinical testingPanel testingScreening panelNew synthetic compoundsClinical interestNew drugsDrugsSubcutaneous modelTreatmentTumorsAntitumor agentsTrialsPotential usefulnessDefinitive answer
1979
Human models of human diseases; breast cancer and the lymphomas
Devita V. Human models of human diseases; breast cancer and the lymphomas. International Journal Of Radiation Oncology • Biology • Physics 1979, 5: 1855-1867. PMID: 393666, DOI: 10.1016/0360-3016(79)90571-6.Peer-Reviewed Original ResearchMultimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects.
Weiss R, DeVita V. Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects. Annals Of Internal Medicine 1979, 91: 251-60. PMID: 380437, DOI: 10.7326/0003-4819-91-2-251.Peer-Reviewed Original ResearchConceptsDisease-free survivalPrimary treatment programGroup of patientsAdvanced diseaseTherapy regimensPrimary lesionSurgical removalAdult malignanciesPalliative treatmentTreatment resultsClinical trialsHuman trialsCancer mortalityChemotherapyMalignancyTreatment programsTreatmentRegimensPatientsLesionsCancerA comparison between combination chemotherapy and total body irradiation plus combination chemotherapy in non‐Hodgkin's lymphoma
Brereton H, Young R, Longo D, Kirkland L, Berard C, Jaffe E, Devita V, Johnson R. A comparison between combination chemotherapy and total body irradiation plus combination chemotherapy in non‐Hodgkin's lymphoma. Cancer 1979, 43: 2227-2231. PMID: 378350, DOI: 10.1002/1097-0142(197906)43:6<2227::aid-cncr2820430611>3.0.co;2-j.Peer-Reviewed Original ResearchTreatment of refractory splenomegaly in myeloproliferative disease by splenic artery infusion.
Canellos G, Sutliffe S, DeVita V, Lister T. Treatment of refractory splenomegaly in myeloproliferative disease by splenic artery infusion. Blood 1979, 53: 1014-7. PMID: 435637, DOI: 10.1182/blood.v53.5.1014.bloodjournal5351014.Peer-Reviewed Original ResearchConceptsSplenic artery infusionArterial infusionBlastic phase of chronic granulocytic leukemiaRefractory to previous therapyPhase of chronic granulocytic leukemiaChronic granulocytic leukemiaResponse to treatmentBlastic phasePrevious therapyMassive splenomegalyMyeloproliferative diseaseSystemic toxicityGranulocytic leukemiaSpleen sizeSymptomatic reliefCytosine arabinosidePatientsSplenomegalyInfusionTreatmentHypersplenismPainLeukemiaTherapyArabinosideTreatment of Refractory Splenomegaly in Myeloproliferative Disease by Splenic Artery Infusion
Canellos G, Sutliffe S, DeVita V, Lister T. Treatment of Refractory Splenomegaly in Myeloproliferative Disease by Splenic Artery Infusion. Blood 1979, 53: 1014-1017. DOI: 10.1182/blood.v53.5.1014.1014.Peer-Reviewed Original ResearchSplenic artery infusionArterial infusionBlastic phase of chronic granulocytic leukemiaRefractory to previous therapyPhase of chronic granulocytic leukemiaChronic granulocytic leukemiaResponse to treatmentBlastic phasePrevious therapyMassive splenomegalyMyeloproliferative diseaseSystemic toxicityGranulocytic leukemiaSpleen sizeSymptomatic reliefCytosine arabinosidePatientsSplenomegalyInfusionTreatmentHypersplenismPainLeukemiaTherapyArabinoside
1978
The chemotherapy of Hodgkin's disease. Past experiences and future directions
Devita V, Lewis B, Rozencweig M, Muggia F. The chemotherapy of Hodgkin's disease. Past experiences and future directions. Cancer 1978, 42: 979-990. PMID: 356960, DOI: 10.1002/1097-0142(197808)42:2+<979::aid-cncr2820420721>3.0.co;2-s.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseCombination chemotherapyAntitumor response rateAdvanced Hodgkin's diseaseComplete remissionDrug therapyDrug combinationsEffective treatmentTherapeutic experimentsAntitumor effectsResponse rateChemotherapyClinical investigatorsNatural historyEffective agentDiseasePatientsMarked increaseTreatmentNitrogen mustardRemissionTherapyPharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
Dedrick R, Myers C, Bungay P, DeVita V. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Journal Of The National Cancer Institute 1978, 62: 1-11. PMID: 626987.Peer-Reviewed Original ResearchConceptsOvarian cancerResidual ovarian cancerTreatment of patientsPharmacokinetic rationalePlasma clearancePeritoneal cavityPeritoneal spaceDrug AdministrationPharmacokinetic calculationsPeritoneal permeabilitySuch drugsCancerAnticancer drugsDrugsTreatmentHydrophilic anticancer drugPatientsAdministrationClearance
1976
Combined modality treatment of American Burkittapos;s lymphoma
Ziegler J, Devita V, Graw R, Herzig G, Leventhal B, Levine A, Pomeroy T. Combined modality treatment of American Burkittapos;s lymphoma. Cancer 1976, 38: 2225-2231. PMID: 1036716, DOI: 10.1002/1097-0142(197612)38:6<2225::aid-cncr2820380606>3.0.co;2-f.Peer-Reviewed Original ResearchConceptsBurkitt's lymphomaCombined modality treatmentBone marrow autograftsMajor therapeutic goalPrevention of relapseThird remissionFirst remissionIntensive chemotherapyComplete responseModality treatmentInitial treatmentAmerican patientsMarrow autograftsRisk factorsClinical trialsTherapeutic goalsPatientsLymphomaRemissionChemotherapyTreatmentImmunotherapyRelapseRadiotherapyAutograft